What does this research mean for the field?

Intensive LDL-C lowering to below 55 mg/dl results in greater plaque stabilization and improved coronary flow compared to LDL-C levels of 56-69 mg/dl in patients with acute coronary syndrome. Novelty: ClaimNovelty.NOVEL_FINDING. Consensus alignment: ConsensusAlignment.SUPPORTS_CONSENSUS.

What question did this study set out to answer?

This study aims to evaluate the effects of intensive low-density lipoprotein cholesterol (LDL-C) lowering therapy on plaque characteristics and coronary flow in non-culprit vessels during acute coronary syndrome.

February 8, 2026

Impact of intensive low-density lipoprotein cholesterol lowering therapy on intermediate stenosis in non-culprit vessels of acute coronary syndrome

Q: What are the key findings of this study?

LDL-C lowering to <55 mg/dl led to greater plaque stabilization and reduced high lipid core plaques (maxLCBI4mm≥400) in non-culprit ACS vessels.

Key Result

LDL-C lowering to <55 mg/dl led to greater plaque stabilization and reduced high lipid core plaques (maxLCBI4mm≥400) in non-culprit ACS vessels.

Key Points

This study aims to evaluate the effects of intensive low-density lipoprotein cholesterol (LDL-C) lowering therapy on plaque characteristics and coronary flow in non-culprit vessels during acute coronary syndrome.
Evaluated 70 patients hospitalized for acute coronary syndrome
Used near-infrared spectroscopy and intravascular ultrasound to assess plaques
Divided patients based on LDL levels at follow-up into two groups: VL and L
Measured changes in lipid core burden index (maxLCBI4mm) and quantitative flow ratio (QFR)
Median LDL levels were significantly lower in the VL group (48 mg/dl) compared to the L group (64 mg/dl)
Greater reduction in maxLCBI4mm in the VL group compared to the L group (P = 0.02)
Lower frequency of plaques with maxLCBI4mm≥400 in the VL group at follow-up
Plaques improved from maxLCBI4mm≥400 to <400 more often in the VL group (P < 0.05)

Structured PICO

Does intensive LDL-C lowering therapy to <55 mg/dl improve plaque stabilization and coronary flow in non-culprit vessels of ACS patients?

Population

70 patients hospitalized for acute coronary syndrome (ACS) with intermediate stenosis in non-culprit vessels evaluated by NIRS-IVUS.

Intervention

Intensive LDL-C lowering therapy achieving LDL-C levels below 55 mg/dl (VL group).

Comparator

LDL-C lowering therapy achieving LDL-C levels 56-69 mg/dl (L group).

Outcome

Change in maximum 4-mm lipid core burden index (delta-maxLCBI4mm) and quantitative flow ratio (delta-QFR) at 12-18 months follow-up.surrogate

Achieving LDL-C levels below 55 mg/dl leads to greater plaque stabilization in non-culprit vessels of ACS patients compared to achieving levels between 56-69 mg/dl.

Main Result

Absolute Event Rate: 0% vs 0%

Abstract

Abstract Background Intensive statin therapy have been shown to reduce cardiovascular adverse events in patients with atherosclerotic diseases 1and lowering low-density lipoprotein cholesterol (LDL-C) significantly can lead to the plaque stabilization in non-culprit vessels in acute coronary syndrome (ACS). The current treatment goal for secondary prevention is to aim to achieve an LDL-C levels to below 55 mg/dl. There are few reports with the association between intensive statin therapy and changes in coronary flow and plaque characteristics. To determine intensive LDL-C lowering therapy on changes in lipid core plaque and coronary flow by Near-infrared spectroscopy and intravascular ultrasound (NIRS-IVUS) and quantitative flow ratio (QFR) in non-culprit vessels of ACS. Purpose The purpose of this study is to determine the impact of intensive LDL-C lowering therapy on changes in coronary flow and lipid core plaque by QFR and NIRS-IVUS in non-culprit vessels of ACS. Methods We prospectively evaluated 70 patients who were hospitalized for ACS and underwent NIRS-IVUS for intermediate stenosis in non-culprit vessels at baseline and at 12–18 month follow-up. According to their LDL levels at follow-up, patients were divided into two groups: VL group with LDL levels below 55 mg/dl and L group with LDL-C levels 56-69 mg/dl. The difference between the maximum 4-mm lipid core burden index (maxLCBI4mm) or QFR values at follow-up and the value at baseline in the intermediate stenosis of non-culprit vessels was defined as delta-maxLCBI4mm or delta-QFR. Result Median LDL levels at follow up were 48 (42-53) mg/dl in the VL group and 64 (60-68) mg/dl in the L group. There was a strong correlation between ΔmaxLCBI4mm and ΔQFR (R2=0.58). The ΔmaxLCBI4mm in the VL group was greater than that in the L group (P =0.02). The presence of plaques with maxLCBI4mm≥400 at follow-up was lower in group VL than in group L. In addition, plaques with maxLCBI4mm≥400 at baseline changed significantly more frequently to maxLCBI4mm400 at follow-up in the VL group (P 0.05). Conclusions Super-aggressive LDL-C lowering therapy for non-culprit intermediate stenosis in ACS has a greater impact on plaque stabilization.

Bookmark